Despite their wishes, many patients die in hospitals or other facilities. Cardiovascular disease (CVD) is the leading cause of death both globally and in the U.S., yet little is known about where patients with CVD die.
Dhruv S. Kazi, MD, MSc, MS, Associate Director of the Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center, writes an accompanying editorial about two new reports showing an association of dog ownership with a better outcome after a major cardiovascular event.
Surgery can mend congenital heart defects shortly after birth, but those babies will carry a higher risk of heart failure for the rest of their lives. UPMC Children’s Hospital researchers found that β-blockers could supplement surgery to mitigate the lasting effects of congenital heart disease.
Dog ownership may be associated with longer life and better cardiovascular outcomes
When a heart attack occurs, muscle in the heart tissue can be scarred, interfering with electrical activity necessary for healthy heart function. Using artificial materials to patch or rebuild damaged parts has been tried but only recently has work focused on the electrical properties needed for proper cardiac operation. In this week’s APL Bioengineering, investigators review the use of electrically conductive biomaterials for heart repair and treatment.
Sophia Antipolis, 07 October 2019: Patients with cancer should receive a tailored exercise prescription to protect their heart, reports a paper published today in the European Journal of Preventive Cardiology, a journal of the European Society of Cardiology (ESC).1
Findings could lead to better understanding of ischemic cardiovascular events and help the development of new treatments
Cardiologist Bertram Pitt, MD, sees promise in combining two new classes of medication into a treatment regimen for patients with cardiovascular disease. Pitt will discuss the advantages of this treatment plan in his plenary lecture at an American Physiological Society Conference in Estes Park, Colo.
A common receptor may serve differentiated roles related to aging-associated cardiovascular disease in males and females. Jennifer DuPont, PhD, will present the findings of this first-of-its-kind study today at the American Physiological Society Aldosterone and ENaC Conference in Estes Park, Colo.
Blocking the mineralocorticoid receptor (MR)—a protein that helps maintain normal levels of salt and water in the body—in immune cells may help reduce the risk of heart attack and stroke by improving blood vessel health. The study will be presented today at the American Physiological Society (APS) Aldosterone and ENaC in Health and Disease: The Kidney and Beyond Conference in Estes Park, Colo.
A new scientific statement from the American Heart Association identifies the risks and benefits of using novel interventional devices compared to anticoagulation alone to treat patients with pulmonary embolism.
Women who reach menopause before the age of 50 have an increased risk of cardiovascular disease, according to researchers from The University of Queensland.
当曾接受冠状动脉旁路移植术(CABG)的患者因胸痛复发而需要二次手术时，大多会施行经皮冠状动脉介入治疗(PCI)，俗称冠状动脉血管成形术及支架植入术。
A new nationwide clinical trial hopes to discover if patients that experience cardiac arrest survive more often and have a better recovery based on how long they have their body temperature cooled.
Aldosterone is a steroid hormone important to the regulation of salt, fluid and potassium in the body. Researchers at the “Metabolic and sex differences in aldosterone responses” symposium will explore the growing body of research that finds sex is a major determinant of how aldosterone acts on the body.
While obesity significantly increases your chances of developing heart failure, for those with established heart failure it may confer a survival benefit compared with normal weight or underweight individuals.
In a medical records study covering thousands of children, a U.S.-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function, it also may be associated with an increased risk of death and kidney failure within a few months or years after surgery.
Research identifies a new target for helping patients decrease risk of heart disease and promote health
MedStar Heart & Vascular Institute has enrolled its first patient to a clinical trial to determine whether cardiac stem cells reduce inflammation enough to improve heart function in patients with heart failure severe enough to require a left ventricular assist device, or LVAD.
Papers on the epigenetic changes to mouse livers induced by a specific ligand and prenatal dexamethasone exposure-induced alterations in neurobehavior in female rat offspring are featured in latest issue of Toxicological Sciences.
روشستر مينيسوتا — عندما يلزم إجراء عملية أخرى لمريض الترقيع التحويلي للشريان التاجي (CABG) بسبب تكرار حدوث ألم في الصدر، يتم ذلك في أكثر الأحيان بالتدخل التاجي عن طريق الجلد (PCI)، والمعروف بشكل عام باسم رأب الأوعية التاجية مع الدعامات.
Quando um paciente submetido a uma cirurgia de revascularização do miocárdio precisa de uma segunda cirurgia devido à recorrência de dores no peito, é muito comum a realização de uma Intervenção Coronária Percutânea (ICP), também conhecida como angioplastia coronária com stents.
Lorsqu'un patient qui a subi un pontage aorto-coronarien (PAC) nécessite une deuxième intervention chirurgicale en raison d'une douleur thoracique récurrente, le plus souvent il s'agit d'une intervention coronarienne percutanée (IPC), communément appelée angioplastie coronarienne, avec des stents.
Wenn ein Koronararterien-Bypass-(CABG)-Patient wegen wiederholter Schmerzen im Brustkorb eine zweite Operation braucht, ist dies häufig eine perkutane Koronarintervention (PCI), gemeinhin als Koronarangioplastie mit Stents bekannt.
The study shows that for those participants who do not have a history of heart disease or stroke that a simple cardiac risk score – a summary measure of factors such as blood pressure, diabetes, smoking, abdominal fat, and dietary factors – is associated with MRI-detected pre-clinical cerebrovascular disease like carotid artery plaque and silent strokes.
A small genetic study, published September 30, 2019 in Nature Genetics, identified a protein linked to many genetic variants that affect heart function. Researchers are expanding the model to other organ systems and at larger scales to create a broader understanding of genes and proteins involved.
Moderate drinking has been linked to a lower risk of coronary heart disease in several studies. However, the relationship between alcohol and heart disease remains controversial and is challenging to assess. Most available data are from prospective (forward-looking) studies of people in middle age or older, in whom alcohol intake was assessed at the time of study entry.
The first randomized trial to compare the safety and efficacy of the new ACURATE neo transcatheter heart valve with the SAPIEN 3 TAVR device did not meet non-inferiority in patients with severe aortic stenosis.
The Portico IDE study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems available in the United States.
The three-year results from the COAPT trial demonstrated that reducing severe secondary mitral regurgitation (SMR) with the MitraClip device safely improves prognosis in selected heart failure (HF) patients. In addition, those patients that crossed over and received the MitraClip after 24 months showed the same benefits as those who received the device at the beginning of the study. Two-year data were presented at TCT 2018 and published in the New England Journal of Medicine.
Five-year results from the PARTNER 2A trial found that patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR.
Patients with left main coronary artery disease (LMCAD) typically have a poor prognosis due to the large amount of myocardium at risk. Revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) has been shown to prolong survival in patients with left main disease compared with medical therapy alone. Three-year data from the large-scale randomized ECXEL trial found no significant difference in the composite rate of death, stroke or myocardial infarction (MI) between the two treatments, with a reduction in 30-day major adverse events with PCI. These results were first reported at TCT 2016 and published in NEJM.
People with heart disease or defective or artificial heart valves are at increased risk of developing a potentially deadly valve infection. Rutgers researchers reported that new risk factors for this condition have emerged and that an increasing number of patients admitted to hospitals for other diseases are at risk of contracting this potentially lethal cardiac infection.
The Geoffrey O. Hartzler Master Operator Award will be presented to Shigeru Saito, MD, in a ceremony on September 27, 2019 at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF).
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not increase myocardial infarction (MI) or stent thrombosis (ST) in high bleeding risk (HBR) patients treated with a contemporary drug-eluting stent.
New data from the randomized, placebo-controlled TWILIGHT trial found that compared to ticagrelor plus aspirin, ticagrelor monotherapy reduces bleeding events without increasing the risk of death, myocardial infarction, or stroke in high-risk patients who have undergone successful percutaneous coronary intervention (PCI) and completed three months of dual antiplatelet therapy (DAPT).
New data from the IDEAL-LM trial found that a biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) was safe and effective compared to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT in patients undergoing PCI for unprotected left main coronary artery (uLMCA) disease.
The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug-coated stent in patients at high risk of bleeding and treated with one-month dual antiplatelet therapy (DAPT) found that both are clinically safe and effective.
Results from international clinical trial ‘TWILIGHT’ could change standard of care for high-risk cases
The TCT Career Achievement Award will be presented to world-renowned cardiologist Robert O. Bonow, MD, MS on September 26, 2019 at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). The award is given each year to an outstanding individual who has made significant contributions to the field of interventional cardiology and transformed patient care through their career endeavors, research pursuits, or mentorship of others.
Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically reduce episodes of rapid, abnormal heartbeats for more than two years, offering hope to patients who have exhausted other treatment options. Findings were presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Cuando un paciente con baipás de la arteria coronaria con injerto necesita una segunda intervención quirúrgica debido a recurrencia del dolor en el pecho, lo más frecuente es realizar una intervención coronaria percutánea, comúnmente conocida como angioplastia coronaria con estent.
International physiologists and researchers studying the kidney, high blood pressure and related medical conditions will convene next week at the American Physiological Society (APS) Aldosterone and ENaC in Health and Disease: The Kidney and Beyond Conference in Estes Park, Colo.
After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right